Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
On August 1, 2017, Titan Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). Summarized below are the results of the matters voted on at the Annual Meeting:
1. Election of Directors
Stockholders elected all of the Company’s nominees for director for one-year terms expiring on the next annual meeting of stockholders. The voting results were as follows:
| FOR | WITHHOLD | BROKER NON-VOTE | |
| Marc Rubin | 4,659,330 | 1,122,080 | 10,399,126 |
| Sunil Bhonsle | 4,578,414 | 1,202,996 | 10,399,126 |
| Joseph A. Akers | 4,853,818 | 927,592 | 10,399,126 |
| Rajinder Kumar | 4,811,295 | 970,115 | 10,399,126 |
| M. David MacFarlane | 4,840,307 | 941,103 | 10,399,126 |
| James R. McNab, Jr. | 4,571,681 | 1,209,729 | 10,399,126 |
| Scott A. Smith | 4,855,492 | 925,918 | 10,399,126 |
2. Ratification of Auditors
Stockholders ratified the appointment of OUM & Co. LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017. The voting results were as follows:
| FOR | AGAINST | ABSTAIN |
| 14,919,041 | 755,406 | 506,089 |
3. Non-binding Advisory Vote on Executive Compensation
Stockholders, on an advisory basis, approved the compensation of the Company’s executive officers. The voting results were as follows:
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
| 3,199,559 | 2,459,118 | 122,733 | 10,399,126 |
About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
